Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei

<u>Field of the invention</u>

0001The invention relates to the field of method and composition for delivering active substance onto cells and/or cell nuclei. More particularly the invention describes amino acid sequences having the capacity to facilitate penetration of a substance of interest such as a drug into cells and/or cell nuclei.

<u>Background</u>

0002There is a need for composition and method able to transfer substances of interest from the outside medium to the inside of cells, and more specifically cell nuclei. Such composition and method are useful to enhance the delivery of drugs into the cytoplasm and/or the cell nucleus from the host organism being treated. An important application of such composition and method concerns the field of gene therapy where selective and non toxic vectors are necessary for introducing DNA into the cell and more specifically cell nuclei.

0003Peptides and amino acid sequences have been proposed to transfer substances of interest from the outside medium to the inside of cells. For example, PCT patent application published under No. WO 01/64738, describes amino acid sequences which react with aminoglycans and transfer a broad range of active substances (biological, pharmaceutical, cosmetic, nutritional, diagnostic or tracer) such as nucleic acids, proteins, drugs, antigens or antibodies.

<u>Summuray of the invention</u>

0004It has been found now new amino acid sequences which can be used both <i>in vivo</i> and in vitro as agents for internalizing substances of interest into cells. Therefore the present invention relates to an amino acid sequence being able to facilitate penetration of a substance of interest inside cells and/or cell nuclei and having the following formula :         (X₁)_p [(X)_o (B)_n X B X X B]_m (X₂)_q     (I)    Wherein    X₁ and X₂ are amino acid sequences of 1 to 20 amino acids;    p and q are whole numbers between 0 and 5;    B is a basic amino acid;    X is a non-basic, preferably hydrophobic amino acid, such as alanine, isoleucine, leucine, methionine, phenylalanine, tryptophan, valine or tyrosine;    n is 2 or 3;    o is 0 or 1.

0005Generally, the amino acid sequence of formula (I) have less than 100 amino acids, less than 50 amino acids is considered better, and less than 25 amino acids better yet.

0006Advantageously, the amino acid sequences according to the invention have between 7 and 25 amino acids, preferably between 7 and 15 amino acids and more preferably between 15 and 25 amino acids.

0007Generally, the amino acid sequence includes a high number of basic amino acids (B) such as lysine, arginine or histidine.

0008"High number" should be understood as at least equal to 3.

0009Preferred amino acid sequences according to the invention are those wherein : <ul id="ul0001" list-style="dash" compact="compact"><li>o is 1, and/or</li><li>p or q is 0, and/or</li><li>X1 or X2 is a sequence of 2 to 5 amino acids, and/or</li><li>n is 2 or 3.</li></ul>

0010Among them, amino acid sequence especially preferred have the following formula :         X B B X B X X B X B B X B X X B     (II)         (X₁)_p X B B B X B X X B X B B B X B X X B     (III)    wherein X₁, X, B and p have the same meaning as above.

0011In another embodiment, several or all L-amino acids of the amino acid sequence above may be changed to D-amino acids.

0012Particularly interesting amino acid sequences according to the invention are :<img file="EP1512696A1_D0001.tif" /><img file="EP1512696A1_D0002.tif" />

<u>Definitions and detailed description of the invention</u>

0013The above amino acid sequences are capable of reacting <i>in vivo</i> with the aminoglycans or glycoaminoglycans and more particularly with heparin, chondroitine sulfates and their derivatives.

0014The mechanism for internalization of the peptide (amino acid sequence) according to the invention, and hence of the substances of interest coupled to said peptide, is therefore dependent on energy. The vectorization using the above peptides is therefore remarkable by the fact that it does not come from a passive system. The amino acid sequences according to the invention are therefore characterized by their capacity to react in vivo with the aminoglycans, the glycoaminoglycans, the aminoglycan sulfates, the chondroitines and the chondroitine sulfates, and to cross cell membrane.

0015The peptides according to the invention are therefore remarkable in that they have the capacity to cross the cell membranes by an active mechanism, then to lodge in the cytoplasm and/or the cell nucleus and thus to make it possible to have a vector whose use is not limited, when it passes into the cell, by the size of the substances being transported. Indeed, the vectors (constituted by or comprising the peptide/amino acid) according to the invention are capable of transporting drugs, ranging from small chemical molecules (low molecular weight) to proteins or plasmid-type nucleic acids (high molecular weight).

0016The use of these vectors thus opens a new path in intracellular protein therapy or gene therapy. This special capacity of the vectors in the invention for penetration makes it possible to target drugs in the cells in a preferential way, thus contributing to a potential reduction in the toxicity of the drugs and a potential increase in the efficacy index.

0017"Heparin or chondroitine sulfate derivatives" or "aminoglycans like heparin or chondroitine sulfate" are understood to mean any product or sub-product as defined in the prior art (Cardin A.D. &amp; Weintraub H.J.R. Arteriosclerosis 9:21 (1989) ; Merton B. et al. Annu. Rev. Cell Biol. 8:365 (1992) ; David G. FASEB J. 7:1023 (1993)).

0018"Facilitate penetration" is understood to mean facilitating the passage or translocation of a substance from the outside medium into the intracellular medium, and quite specifically into the cytoplasm and/or the nucleus of the cell. This penetration can be determined by various processes, for example by a cell penetration test having a first incubation step for the amino acid sequence in the presence of culture cells, followed by a fixing step and permeabilization of those cells, and then revelation of the presence of said amino acid sequence inside the cell. The revelation step can be done with another incubation in the presence of antibodies marked and directed against said sequence, followed by detection in the cytoplasm or in immediate proximity of the cell nucleus, or even within it, of the immunologic reaction between the sequence and the marked antibodies. Revelation can also be done by marking an amino acid sequence in the invention and detecting the presence of said marking in the cell compartments. A cell penetration test was described in patent application No. WO 97/02840.

0019"Substance of interest" is understood to mean any product presenting an interest, particularly biological, pharmaceutical, diagnostic, tracing, or agro-food. They can be nucleic acids (DNA, RNA, siRNA, dsRNA, ssRNA, aRNA) that can have various origins, and particularly, human, viral, animal, eukaryotic or prokaryotic, vegetable, synthetic, etc., and able to vary in size, ranging from a simple oligonucleotide to a genome or genome fragment. It can also be a viral genome or plasmid. The substance can also be a protein, such as an enzyme, a hormone, a cytokine, an apolipoprotein, a growth factor, an antigen, an antibody, etc. It can also be a toxin, antibiotic, antiviral molecule or immune modulator. It can also be a polymer-type component, such as a microsphere or a nanosphere.

0020Generally, the substance of interest can be any active ingredient of a drug, whether it be a chemical, biochemical, natural or synthetic product. The molecules can be small, with a molecular weight of around 500D, or large like proteins of several thousand Daltons.

0021The substance of interest can be directly active or can be activated <i>in situ</i> by a distinct agent or by environmental conditions. The scope of the invention extends to combinations of the amino acid sequence with a substance of interest as defined above.

0022Another preferred type of sequences according to the invention is constituted by i) a first amino acid sequence as defined above and ii) a second amino acid sequence corresponding to an antibody fragment.

0023In that embodiment, the first amino acid sequence is coupled (directly or indirectly linked) to the second amino acid sequence.

0024The second amino acid sequence (peptide) derives advantageously from the variable part of human anti-DNA antibodies.

0025The coupling of the amino acid sequences and peptides derived from variable parts of human anti-DNA antibodies inside one and the same molecule results in the preparation of a peptide vector that is particularly effective in translocation and intracellular transfer of substances of interest.

0026This combination also gives rise to a translocation and transfer vector specially adapted for use in humans. Indeed, as indicated above, although the peptide vectors of murine origin known from WO 97/02840 are coded by the germinal line and carry no mutations, and consequently should be close to those encountered in humans in terms of antigens, it is possible that their injection into humans would induce an immune reaction. The peptide vector formed from amino acid sequences according to the invention and from peptides derived from anti-DNA antibodies prevents this problem.

0027The general characteristics of these peptides derived from human anti-DNA antibodies are close to those of the peptides of murine origin described in patent application WO 99/07414, while they have additional properties that distinguish them from the latter, namely: <ul id="ul0002" list-style="none" compact="compact"><li>1) To penetrate inside cells, they have to have an active cell metabolism (culture temperature between 25ºC and 39ºC, preferably and 37ºC), while the murine peptides are clearly less dependent;</li><li>2) They react much less strongly with DNA than the murine vectors;</li><li>3) Their penetration capacity is not significantly influenced by the molecule they are going to transport inside the cell;</li><li>4) They penetrate better inside cells of human origin than inside cells of other origins.</li></ul>

0028The amino acid sequences (peptides) as defined above are capable of transporting inside cells molecules that are combined with them covalently or non-covalently, and are thus effective vectors for intracellular transfer of the substances of interest.

0029As shown in the example relating to internealization of DPV-antiPO IgG (see figure 18), the peptides according to the invention are capable of tansporting inside cells molecules that remain active once inside the cells.

0030Therefore, the present invention is aimed at using the amino acid sequences defined above to prepare compositions designed to transfer substances of interest into cells. This capacity of the peptides in the invention is an advantage to allow the transport of active substances through biological membranes and, quite specifically, through the hematoencephalic, hematoretinal, intestinal and pulmonary barriers. The peptides in the invention have the interest of being able to be used in forms of administration adjusted to both the active substance to which they are coupled and to the type of cell targeted, particularly those requiring passage through the above barriers.

0031In another embodiment, the present invention relates to the use of said amino acid sequences as a peptide vector. These vectors, due to the properties of said amino acid sequences, can be used easily for intracytoplasmic, intracytosolic and /or intranuclear transfer in humans, with no risk to them or any degradation of the substance of interest coupled to the vector.

0032A vector according to the present invention is characterized by the fact that it is composed of, or includes, an amino acid sequence as defined above.

0033As indicated above, a vector may also comprise one or more antibody fragments, preferably polyreactive, and more specifically one or more fragments that come from hypervariable regions of the antibody, linked to an amino acid sequence according to the invention. Preferably, the vector that is the subject of the invention is characterized by the fact that it contains a fragment of the heavy chain of an antibody.

0034The subject of the present invention is a vector for cell internalization, characterized by the fact that it contains one or more amino acid sequences according to the invention and one or more fragments of an IgM or an IgG.

0035Preferably, said vector contains all or part of the CDR2 region of an antibody. As a variation, said vector contains all or part of the CDR3 region of an antibody. More specifically, said vector contains at least one CDR3 region of an anti-DNA human antibody, selected from the group consisting of RTT79, NE-1 and RT72.

0036In another embodiment, the vector can also contain all or part of region CDR2, and all or part of region CDR3.

0037By "all or part" it is understood that the vector can contain either the whole CDR region concerned, or only part of it, provided that the vector retains the capacity to penetrate into the cells (functional homologue). By "part of CDR region" is understood a CDR region deprived of one or more terminal amino acids. It can also be a CDR region in which one or more internal residues have been deleted or substituted for other amino acids, preferably amino acids of the same nature (basic amino acids, for example).

0038As indicated above, the vector in the invention is particularly well suited for intracellular and intranuclear transport and transfer of substances of interest.

0039The present invention is therefore aimed at supplying a vector such as the one described above, characterized by the fact that it contains a substance that can be incorporated into the cells and/or the nuclei of said cells.

0040More specifically, the present invention is directed to a vector whose penetration capacity is quite independent from the nature of the substance of interest that is coupled to it. This characteristic, proper to these human vectors compared to the murine vectors, is of primary interest in the planned use of these vectors. But the invention is also interested in vectors that are adapted to the substance of interest which is coupled to it.

0041"Coupling" is understood to mean any type of interaction allowing a physical association between the substance of interest and the vector. It can be cleavable or non-cleavable according to the biological medium and/or the substance of interest transported by the peptides of the invention or it can be cleavable by physical means applied to the organism to which the vector coupled to the active substance has been administered. Thus, the expression of the biological effect of the substance can require that it be released from the vector. Doxorubicin can be cited as an example of a substance of interest that is preferably released from the vector.

0042However, the interaction must be solid enough that the vector does not dissociate before or during cell penetration. For this reason, the coupling preferred in the invention is covalent coupling, although it can be noncovalent coupling. The substance of interest can be coupled directly to the peptide either on one of those terminal ends or on a side chain or one of the amino acids. The substance of interest can also be coupled indirectly by a connecting arm either to one of the terminal ends of the peptides or to a side chain of one of the amino acids.

0043The coupling can be done by any chemical, biochemical, enzymatic or genetic coupling process known to a person skilled in the art, but it is generally preferred to use a homofunctional or heterofunctional bridging reagent like succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC). Other coupling means that can be cited are those chosen from among: bi-functional or multi-functional agents containing alkyl, aryl, aralkyl or peptide groups; esters; aldehydes or alkyl, aryl or aralkyl acids; anhydride, sulfhydrile or carboxyl groups such as maleymil benzoic acid and maleymil propionic acid derivatives and succinimidyl derivatives; groups derived from bromide or cianogenic chloride, carbonyldiimidazole, succinimide esters or sulphonic halogenides.

0044In another form of embodiment of this invention, said substance of interest can also be coupled by any genetic engineering technique known to a person skilled in the art. "Genetic engineering" means using an expression vector in which the DNA coding for peptide vectors is cloned in phase in 5' and/or 3'of the complementary DNA of the gene of interest. Expression of the fusion protein is under the control of a promotor. The expression system can be used in a prokaryotic or eukaryotic host cell for the production of the fusion protein.

0045In a first embodiment, said substance of interest is coupled at the N-terminal end of the amino acid sequence of the amino acid sequence according to the invention. In a second embodiment, said substance of interest is coupled at the C-terminal end of said sequence.

0046Surprisingly, it has been shown that the vector according to the present invention is capable of potentiating the biological activity and, potentially, reducing the toxicity of said coupled substance. More particularly, the use of the vector offers the possibility to overcome the drug resistance developed by a subject against an active substance such as an anti-cancer molecule.

0047This invention therefore also has as its subject a vector characterized by the fact that it makes it possible to increase the biological activity of the substance of interest to which it is coupled.

0048It has also been shown that the vector that is the subject of the invention permits transfection of cells <i>in vitro.</i>

0049In one particular embodiment of the invention, the vector is coupled to the substance of interest by at least one molecule, called an "anchoring molecule", that has a strong natural affinity for the substance of interest to be internalized. The natural affinity of the anchoring molecule for the substance of interest allows the transporter to interact non-covalently with said substance of interest, and hence to carry it along in intracellular travel.

0050Another especially interesting advantage of this type of transporter consists of the fact that, due to the natural affinity of the anchoring molecule for the substance of interest, these two elements are coupled in a totally natural way, with no chemical or biochemical interaction.

0051This type of transporter is particularly interesting in a case where the substance of interest, due to its size and/or its structure, proves difficult to couple directly to the amino acid sequence. This type of transporter can also prove particularly useful when the substance of interest is not very stable, and when any kind of chemical interaction for coupling it could degrade it or alter its activity.

0052In addition, the transporter cannot be specific for a single substance of interest, but can, on the contrary, permit internalization of several different substances of interest inside cells and/or cell nuclei.

0053The present invention also concerns eukaryotic cells that contain an amino acid sequence as defined above. It also concerns eukaryotic cells that contain an amino acid sequence, a vector and/or a transporter according to the invention. It also concerns any type of eukaryotic cell that has been transfected by a vector and/or transporter according to this invention.

0054The invention also relates a process to transfer a substance of interest inside a cell <i>in vitro</i> and to increase the biological activity of said substances of interest that has the following steps: <ul id="ul0003" list-style="none" compact="compact"><li>a) coupling the substance to an amino acid sequence, to a vector or to a transporter according to the invention, as described above, and</li><li>b) incubating the cell with said coupling product at a culture temperature that permits active metabolism of said cell.</li></ul>

0055Such a temperature is between 25ºC and 39ºC, preferably 37ºC.

0056This invention is also directed to a composition having as active ingredient either amino acid sequences, vectors or transporters "loaded" with at least one substance of interest, or eukaryotic cells that have been transfected according to the invention. Its subject is also the use of such compositions for the formulation and preparation of biological, pharmaceutical, cosmetic and agro-food products.

0057The term "loaded" refers, as indicated above, to an amino acid sequence, vector or transporter according to the invention, linked directly or undirectly, or conjugated with at least one substance of interest.

0058The scope of the invention extends to pharmaceutically acceptable alkaline or acidic addition salts, hydrates, esters, solvates, precursors, metabolites or stereoisomers, of said vectors and transporters loaded with at least one substance of interest. The scope of the invention also extends to pharmaceutical formulations having a vector or transporter loaded with at least one substance of interest in combination with a pharmaceutically acceptable vehicle, diluent or excipient.

0059The expression "pharmaceutically acceptable salts" refers to non-toxic salts of the amino acid sequences in the invention that can generally be prepared by having the free base react with a suitable organic or inorganic acid. These salts retain their biological efficacy and the properties of the free bases. Representative examples of said salts that can be cited are water-soluble and water-insoluble salts, such as acetates, ansonates (4,4-diaminostilbenes-2,2'-disulfonates), benzene sulfonates, benzonates, bicarbonates, bisulfates, bitartrates, borates, bromides, butyrates, calcium edetates, camsylates, carbonates, chlorides, citrates, clavulariates, dichlorohydrates, edetates, edisylates, estolates, esylates, fumarates, gluceptates, gluconates, glutamates, glycolylarsanylates, hexafluorophosphates, hexylresorcinates, hydrabamines, hydrobromides, hydrochlorides, hydroxynaphthoates, iodides, isothionates, lactates, lactobionates, laurates, malates, maleates, mandelates, mesylates, methyl bromides, methyl nitrates, methyl sulfates, mucates, napsylates, nitrates, 3-hydroxy-2-naphthoates, oleates, oxalates, palmitates, pamoates (1,1-methylene-bis-2-hydroxy-3-naphtoates, emboates), pantothenates, phosphates/diphosphates, picrates, polygalacturonates, propionates, p-toluene sulfonates, salicylates, stearates, subacetates, succinates, sulfates, sulfosalicylates, suramates, tannates, tartrates, teoclates, tosylates, triethiodides, valerates and salts of N-methylglucamine ammonium.

0060A subject can be treated with a pharmaceutically effective quantity of a peptide, a vector or a transporter according to the invention, loaded with at least one substance of interest. The expression "pharmaceutically effective quantity" means a quantity capable of making the substance of interest penetrate sufficiently to induce the biological or medical response of a tissue, system, animal or human as expected by the researcher or attending physician.

0061The invention also covers pharmaceutical compositions suitable for the introduction of a substance of interest into a cell or cell nucleus. The compositions contain an effective quantity of aan amino acid sequence, a vector or a transporter according to the invention, "loaded" with at least one substance of interest, alone or in combination with one or more pharmaceutically acceptable supports. The compositions are particularly useful in the sense that they have very low toxicity, or are non-toxic.

0062The vectors or transporters according to the invention, or their salts, "loaded" with at least one substance of interest, can be administered by any of the routes of administration accepted for therapeutic agents. These processes include systemic administration, for example oral, nasal, parenteral or topical administration, for example transdermal or even central administration, for example by the intracranial surgical route or intraocular administration.

0063Oral administration can be used by means of tablets, gel capsules, soft capsules (including delayed or extended-release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions. This form of presentation is particularly suitable for passage through the intestinal barrier.

0064Parenteral administration is generally done by subcutaneous, intramuscular or intravenous injection or by perfusion. The injectable compositions can be prepared in the traditional forms, either in suspension or liquid solution or in solid form for extemporaneous dissolution in a liquid. This form of presentation is more specifically adapted for passage through the hematoencephalic barrier.

0065One possibility of parenteral administration uses implantation of a slow or extended-release system that makes sure a constant dosage level is maintained, for example according to US-A-3 710 795.

0066For intranasal administration, suitable intranasal vehicles can be used.

0067For transdermal administration, transdermal cutaneous stamps well known to a person skilled in the art can be used. A transdermal-release system permits continuous administration.

0068Other preferred topical preparations include creams, unguents, lotions, aerosol sprays and gels.

0069Based on the planned route of administration, the compounds can come in solid, semi-solid or liquid form.

0070For the solid compositions, such as tablets, pills, powders or granules in the free state or included in gel caps, the active ingredient can be combined with: a) diluents, for example lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, for example silicone, talc, stearic acid, its magnesium or calcium salt and/or polyethylene glycol; c) binders, for example magnesium and aluminum silicate, starch paste, gelatin, tragacanth gum, methyl cellulose, sodium carboxymethyl cellulose and/or polyvinyl pyrrolidone; if necessary, d) disintegrators, for example, starch, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, dyes, aromatic agents and sweeteners. The excipients can be, for example, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talc, cellulose, glucose, sucrose, magnesium carbonate and pharmaceutical quality analogs.

0071For semi-solid compositions, such as suppositories, the excipient can be, for example, an emulsion or fatty suspension, or one with a polyalkylene glycol base, such as polypropylene glycol.

0072The liquid compositions, particularly injectables or those to be included in a soft capsule, can be prepared, for example, by dissolution, dispersion, etc. of the active ingredient in a pharmaceutically pure solvent such as, for example, water, physiological serum, aqueous dextrose, glycerol, ethanol, an oil and the like.

0073The amino acid sequence, vectors or transporters accoring to the invention, "loaded" with at least one substance of interest, can also be administered in the form of liposome-type release systems, such as in the form of small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. The liposomes can be made from a variety of phospholipids, containing cholesterol, stearoylamine or phosphatidyl cholines. In one form of embodiment, a film of liquid components can be hydrated with an aqueous solution of the drug to form a lipid layer encapsulating the medication, as described in US-A-5 262 564.

0074It can be sterilized and/or contain adjuvants and non-toxic auxiliary substances, such as preserving, stabilizing, wetting or emulsifying agents, agents promoting dissolution, salts to regulate osmotic pressure and/or buffers. They can also contain other substances that have therapeutic interest. The compositions are prepared, respectively, by traditional mixing, granulating or coating processes, and they contain around 0.1% to 75%, preferably around 1% to 50% active ingredient.

0075The amino acid sequences, vectors or transporters of the invention, "loaded" with at least one substance of interest, can also be coupled with soluble polymers, such as targetable drug supports. Such polymers can contain polyvinyl pyrrolidone, pyrane copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxy-ethyl-aspanamide-phenol or poly (ethylene oxide)-polylysine substituted with palmitol residues. The compounds in this invention can also be coupled to a class of biodegradable polymers useful in producing controlled release of a drug, for example, poly(lactic acid), poly(epsilon-caprolactone), poly(hyroxybutyric acid), the polyortho esters, the polyacetals, the polydihydropyranes, the polycyanoacrylates and the reticulated or amphipathic sequenced hydrogel copolymers.

0076The dosage for the administration of the amino acid sequences vectors or transporters of the invention, loaded with at least one substance of interest, is chosen depending on a diversity of factors including the type, species, age, weight, sex and medical condition of the subject; the seriousness of the condition being treated; the route of administration; the status of the subject's kidney and liver functions, and the nature of the particular compound or salt used. A regularly experienced physician or veterinarian will easily determine and prescribe the effective quantity of the vector or transporter loaded with the substance of interest in order to prevent, thwart or stop the progress of the medical condition being treated.

0077Any of the above pharmaceutical compositions can contain from 0.1% to 99%, preferably 1% to 70%, of the active ingredient.

0078As examples, the oral dosages of the amino acid sequences, vectors or transporters of the invention, loaded with at least one substance of interest, when they are used for the effects indicated, will be between around 0.05 and 1,000 mg/day by the oral route and, preferably come in the form of tablets containing 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100.0, 250.0, 500.0 and 1,000.0 mg of active ingredient. The effective plasma levels of the vectors or transporters loaded with at least one substance of interest will range from 0.002 mg to 50 mg per kilogram of body weight and per day.

0079The amino acid sequences, vectors or transporters of the invention, loaded with at least one substance of interest, may be administered in the form of single daily doses, or the total daily dose may be administered in two, three or four doses per day.

0080In one particular application, the present invention relates to a diagnostic agent for <i>in vitro</i> use, composed of or containing at least one amino acid sequence, vector, transporter and/or one cell according to the invention. Such a diagnostic agent can also be used <i>in vivo.</i>

0081The subject of this invention is therefore also a diagnostic kit that includes said diagnostic agent. More specifically, the diagnostic kit includes a predetermined quantity of a composition according to the invention, in one or more containers.

0082Similarly, the amino acid sequence in the invention, or a vector and/or a transporter containing that amino acid sequence, or cells transfected with the help of said vector, can be used <i>in vivo</i> for preventative purposes, for example and in a non-limiting way, for the prevention of viral infections, metastases, cell apoptosis (degenerative diseases, tissue ischemia...), or for therapeutic purposes, for example the treatment of infectious diseases (viral, bacterial...), cancer and pathological neo-angiogenesis.

<u>Brief description of the figures</u>

0083<ul id="ul0004" list-style="none" compact="compact"><li>Figure 1 shows EZ-Link Maleimide Activated Horseradish Peroxidase. M.W = 40.000. R represents either DPVs or cysteine.</li><li>Figure 2 shows example of SDS-PAGE separation of the DPV-PO conjugates. A : 15 µg of each DPV-HRP conjugate was loaded on a 10 % SDS-PAGE gel. B : molecular weight calculation for each conjugate (Bioprofil software).</li><li>Figure 3 shows quantitative penetration of the DPV-PO conjugates in HCT116 cells.</li><li>Figure 4 shows quantitative penetration of the DPV-PO conjugates in HeLa cells.</li><li>Figure 5 shows the comparison of the level of internalization of the DPV15-PO, DPV15b-PO and DPV10-PO conjugates in HeLa and HCT116 cells.</li><li>Figure 6 shows localization of the DPV-PO conjugates in HeLa cells.</li><li>Figure 7 shows immunofluorescent staining of DPV15b-PO and DPV15-PO conjugates after internalization in HeLa cells for 4 hours at 37°C.</li><li>Figure 8 shows internalization of DPV-PO conjugates as a function of the initial conjugate concentration.</li><li>Figure 9 shows influence of the temperature on the level of internalization of DPV-PO conjugates.</li><li>Figure 10 represents comparative levels of internalization of DPV15b-PO and Cys-PO in CHO and PgsA-745 cells.</li><li>Figure 11 shows inhibitory effect of heparin on the intracellular accumulation of DPV-PO conjugates.</li><li>Figure 12 shows inhibitory effect of Poly-L-Lys on the intracellular accumulation of DPV-PO conjugates.</li><li>Figure 13 shows example of SDS-PAGE separation of the DPV-Anti PO IgG conjugates.</li><li>Figure 14 shows quantitative penetration of the DPV-AntiPO IgG conjugates in HCT116 cells.</li><li>Figure 15 shows quantitative penetration of the DPV-antiPO IgG conjugates in HeLa cells.</li><li>Figure 16 represent a comparison of the level of internalization of the DPV15-antiPO, DPV15b-antiPO and DPV10-antiPO conjugates in HeLa and HCT116 cells.</li><li>Figure 17 shows localization of DPV15-antiPO IgG and DPV15b-antiPO IgG conjugates in HeLa cells.</li><li>Figure 18 shows immunofluorescent staining of DPV15-antiPO IgG and DPV15b-antiPO IgG conjugates after internalization in HeLa cells for 4 hours at 37°C.</li><li>Figure 19 shows immunofluorescent staining of DPV15b-antiPO IgG conjugates after internalization in HCT116 cells for 4 hours at 37°C. It shows the intracellular localization of DPV15b-IgG conjugates in HCT116 cells.</li><li>Figure 20 shows quantitative penetration of the DPV15-and DPV15b-TMR in HeLa cells.</li><li>Figure 21 shows quantitative penetration of the DPV15-and DPV15b-TMR in HCT116 cells.</li><li>Figure 22 represents a comparison of the level of internalization of the DPV-TMR in HeLa and HCT116 cells.</li><li>Figure 23 shows cytoplasmic punctuate staining of DPV15b-TMR after internalisation in HeLa cells.</li><li>Figure 24 shows cytoplasmic punctuate staining of DPV15b-TMR after internalisation in HCT116 cells.</li><li>Figure 25 shows the influence of the temperature on the level of internalisation of DPV15b-TMRconjugates.</li><li>Figure 26 shows quantification of DPV15b-TMR conjugates internalisation in CHO and PgsA-745 cells.</li><li>Figure 27 shows Chlorambucil formula.</li><li>Figure 28 and 29 represent Chlorambucil conjugated to DPV15 with an ester link (E) on the OH group.</li><li>Figure 30 represents Paclitaxel formula with its reaction sites.</li><li>Figure 31 represents DPV15-E-PTX formula.</li></ul>

<u>Examples</u>.

0084Other advantages and characteristics of the invention will appear from the following examples which refer to the above figures. The example are given to illustrate the invention but not to limit the scope of the claims.

<u>Example 1 : Internealization of control molecule without biological effect (Peroxidase)</u>.

1) <u>Materials and Methods</u>.

1.1)

Nature of the ligand

.

0085Peroxidase was chosen to represent the capacity of the DPV15 and DPV15b to internalize medium size proteins (40 000 Da). The use of a preactivated form of the protein allows the preparation of homogenous conjugates (only 1 DPV per PO molecule). Penetration of DPV-PO conjugates was tested in both HCT116 (colorectal carcinoma) and HeLa (cervix adenocarcinoma) cell lines. <ul id="ul0005" list-style="dash" compact="compact"><li>EZ-Link Maleimide Activated Horseradish Peroxidase. (Pierce 31485). EZ-Link Maleimide Horseradish Peroxidase (PO) (M.W = 40.000) is used for an easy preparation of peroxidase conjugates. It is a pre-activated and stable PO derivative that reacts with sulfhydryl (-SH) groups. This product can be used to conjugate PO to any ligand that contains a free -SH group.</li><li>Peptide Vectors.    DPV15 : Leu Arg Arg Glu Arg Gln Ser Arg Leu Arg Arg Glu Arg Gln Ser Arg (SEQ ID NO.1) with a cystein residue at its C terminal end for coupling a substance of interest,    DPV15b : Gly Ala Tyr Asp Leu Arg Arg Arg Glu Arg Gln Ser Arg Leu Arg Arg Arg Glu Arg Gln Ser Arg (SEQ ID NO.2) with a cystein residue at its N terminal end for coupling a substance of interest,    DPV15 and DPV15b may comprise a cystein residue at one or both of their N or C terminal ends for coupling a substance of interest,    DPV10 : Ser Arg Arg Ala Arg Arg Ser Pro Arg His Leu Gly Ser Gly (SEQ ID NO.3) with a cystein residue at its C terminal end for coupling a substance of interest (this sequence has been disclosed in the PCT patent application published under No. WO 01/64738).</li><li>Vivaspin (vivascience): ultrafiltration membrane (6 mL / cutoff threshold = 10000 Daltons), used for concentration and purification of the conjugated compounds (elimination of excess reagent).</li><li>Free peroxidase (SIGMA ref P-6782) used for controls.</li></ul>

1.2)

Conjugation protocol

.

0086Dissolve 500 µg of DIATOS peptide in 50 µl of conjugation buffer (NaCl 0.5M, Sodium phosphate 50 mM, EDTA 5 mM pH 7).

0087Dissolve 1mg of Maleimide Activated Peroxidase in 200µl of conjugation buffer.    Add 43 µl of DIATOS peptide to 1mg (200µl) of Maleimide Activated Peroxidase (Molar Ratio: 5 pept / PO-Maleimide)    Mix and incubate 3 hours at room temperature    Add 1 ml of 0.5M NaCl    Concentrate DPV-PO with vivaspin. Centrifugation 10-15 min, 3300g, 20°C    Refill vivaspin with 2 ml of 0.15 M NaCl and concentrate conjugate again    Repeat this last step one time.

0088A control was made which consists of PO linked to Cystein.

1.3)

Conservation of the conjugates

.

0089DPV-PO conjugates are kept frozen (-20°C), diluted in 0.15 M NaCl.

1.4)

Characterization of the conjugated compounds

.

a)

SDS-PAGE.

009015 µg of each sample are loaded on a 10 % acrylamide SDS-PAGE gel.

0091Migration 100 V - 1 hour.

0092Staining of the gel with brilliant blue coomassie solution for 1 hour.

0093Destaining for 1 hour in H₂O / Ethanol / Acetic acid. (6V / 3V / 1V).

0094Figure 2A shows an increase of molecular weight after coupling (band 1 is lower in lane 2 than in lanes 3 and 4). The table in figure 2B shows the result of calculation of the conjugates molecular weight with the bioprofil software. For every conjugate, there is an increase of approximately 2 kDa, corresponding to the molecular weight of the DPVs that were added to the PO molecule. The presence of a single band in lanes 3 and 4 shows that the only molecule in solution is actually DPV-PO conjugate, and that there is no free PO in solution.

b) ELISA test on Heparin coated plates.

0095DPV-PO conjugates and controls (free PO and Cys-PO) are loaded on an ELISA plate previously coated with 5 µg/ml heparin (so that only conjugated compounds will bind and react with PO substrate).

0096Diluted samples (30 ng/ml) are incubated 1 hour at 37 °C, and washed 5 times in PBS containing 0.1 %Tween.

0097Staining is obtained with PO substrate (O-Phenylenediamine Dihydrochloride (OPD) (Sigma) tablets) - 5 mg pills diluted in 10 ml citrate-citric acid buffer 0.1 M + 100µl H₂O₂ 3%).

0098Reaction is stopped by addition of 50µl H₂SO₄ 2N.

0099O.D. read at 490 nm.

0100This test allows the detection of conjugate in solution, as another verification of the results shown in figure 2A. However, it does not allow its quantification, possible only after the experiment described in II.4.c.

c)

Determination of the concentration of the conjugated compounds in solution

.

0101The quantification of DPV-PO conjugates in solution is realized after verification of a proper coupling by Elisa, and is based on the activity of the PO protein itself, assuming that there is no free peroxidase in solution.

0102Standard dilutions for free PO (from 10 ng/ml, then _ dilutions).

0103Dilution of the DPV-PO samples 1/160 000, then _ dilutions.

010450 µl of solution in a well of a 96 well Elisa plate.

0105Add PO substrate (OPD).

0106Stop reaction after 9 min by addition of 50µl H₂SO₄ 2N.

0107Read O.D. at 490 nm and compare with the one obtained for free PO.

1.5)

Internalization protocol

.

0108Internalization experiments were realised in both HCT116 (colorectal carcinoma) and Hela (cervical adenocarcinoma) cell lines. Internalization was initially evaluated at a single time point (4 hours).

0109HCT 116 culture medium : Mc Coy's 5a (Gibco BRL) + 1.5 mM L-glutamine + 10 % SVF.

0110HeLa culture medium : DMEM (Gibco BRL) + 2 mM L-glutamine + 1 mM Na Pyruvate + 10 % SVF.

a)

Quantitative assay

.

0111Cells were routinely seeded at Day 0: 3.6.10⁴ cells/cm² for HeLa cells, or 7.10⁴ cells/cm_ for HCT116 cells, in 8 wells labtek glass slides (0.7 cm²/well). Penetration studies are performed at Day1.

0112<u>Protocol</u> : (Proceeding MM-08/11/01v1)

0113Dilute conjugates in DMEM + 10% FCS at 75 µg/ml.

0114Take culture medium off the cells

0115Incubate conjugates for 4 hours, 37 °C, 5% CO₂ - 100 µl/well (i.e.7.5 µg/well).

0116Rinse cells 3 times in PBS.

0117Incubate the cells in 100 µl Trypsin-EDTA for 30 min at 37°C.

0118Resuspend cells in 150 µl of complete culture medium.

0119Count cells.

0120Centrifuge and rinse cells twice in ice cold PBS.

0121Resuspend in 220 µl cold lysate buffer (0.1M Tris pH8, 0.5 % NP40).

0122Incubate 15 min at 4°C.

0123Centrifuge cell lysates.

0124Distribute 100µl per well in a 96 wells plate.

0125Prepare a peroxidase standard curve in lysis buffer (from 10 ng/ml. Diluted in PBS. 10 points). Count the tested solution, to calculate % of internalization.

0126Add soluble peroxidase substrate (1 pill of 5mg OPD (Sigma) + 10 ml citrate-citric acid buffer 0.1 M, pH5.5 + 100 µl 3 % H₂O₂)

0127Stop the reaction after 9 min by adding 50 µl H₂SO₄ 2 N.

0128Read absorbance at 490 nm.

b)

Qualitative evaluation of the internalization of DPV-PO conjugates

.

0129Cells were routinely seeded at Day 0 on 8 wells glass labteck slides (1 cm²), in the following conditions: 0.3 10⁵ cells/well for CHO cells, 0.25 10⁵ cells/well for PgsA-745 cells and HeLa cells. Seeding was always performed in 250 µl of medium. Penetration studies are routinely performed at Day 1 for all these cell lines.

0130<u>Protocol</u> : (Proceeding FC-14/01/02/vl)

0131Dilute conjugates in DMEM + 10 % SVF at the proper concentration.

0132Take culture medium off the cells

0133Incubate conjugates in the proper conditions.

0134Rinse cells 3 times in PBS.

0135Fix in 3.7 % PFA for 20 min at room temperature (RT).

0136Rinse in PBS at RT.

0137Perform the immunostaining with the proper antibodies, the secondary being conjugated to a fluorochrome.

0138Mount in the presence of Dapi.

2) <u>Results</u>

.

2.1)

Quantitative intracellular accumulation

.

0139Figure 3 shows quantitative penetration of the DPV-PO conjugates in HCT116 cells. Cell lysis was performed after 4 hours of incubation at an initial DPV-PO conjugates concentration of 75 µg/ml (corresponding to approximately 1.8 mM). Results are given as the mean value obtained in three independent experiments, all realized in duplicates.

0140Table 2 represents net quantities of DPV-PO conjugates internalized in HCT 116 cells. Results are given in picograms / 1000 cells. <tables id="tabl0001" num="0001"><img file="EP1512696A1_D0003.tif" /></tables>

0141Figure 4 shows quantitative penetration of the DPV-PO conjugates in HeLa cells. Cells were incubated for 4 hours in the presence of the conjugates at an initial concentration of 75 µg/ml. Results are given as the mean value obtained in three independent experiments, all realized in duplicates.

0142Table 2 represents net quantities of DPV-PO conjugates internalized in HeLa cells. Results are given in picograms / 1000 cells. <tables id="tabl0002" num="0002"><img file="EP1512696A1_D0004.tif" /></tables>

0143Figure 5 shows the comparison of the level of internalization of the DPV-PO conjugates in HeLa and HCT116 cells.

0144<u>Table 4</u>: Estimated number of conjugate molecules internalized in each cell type (million conjugate molecules per cell) and ratio of intracellular accumulation of DPV-PO conjugates in HeLa versus HCT116 cells. <tables id="tabl0003" num="0003"><img file="EP1512696A1_D0005.tif" /></tables>

0145As can be seen in figures 4-6 and table 1-3, the level of DPV-PO intracellular accumulation is variable, as a function of the DPV, and as a function of the cell line.

2.2)

Qualitative evaluation of the internalization of DPVs-peroxidase in HeLa cells

.

0146DPV-PO conjugates were incubated with HeLa cells cultivated on glass labtek slides (4 hours incubation of a 75 µg/ml solution in DMEM + 10%FCS, at 37 °C). The experiment was realized with the same peptide-PO conjugates as the ones used in the quantitative experiments described above, in the exact same conditions.

0147Figure 6 shows localization of the DPV-PO conjugates in HeLa cells.

0148DPV-PO conjugates were incubated for 4 hours at an initial concentration of 75 µg/ml on HeLa cells, on 8 wells labtek glass slides. Revelation of peroxidase was performed using di-aminobenzidine, as described in section III-2. Pictures were taken with a Nikon coolpix numeric camera, maximum zoom, after visualization on a Leica microscope (20 X lens + 0.63 X adaptator).

0149Figure 6 shows typical images of what can be observed after penetration of the conjugates in HeLa cells and di-aminobenzidine (DAB) revelation of peroxidase. DPV15-PO and DPV15b-PO were clearly always mainly nuclear.

0150Figure 7 shows details of HeLa cells after DPV15b-PO internalization. Pictures were taken in the same conditions as described above for figure 6. Numeric enlargement was obtained afterwards.

0151Figure 7 shows more precisely what can be observed. For DPV15b-PO, nuclei and nucleoli are clearly stained and the cytoplasm is also stained, though much more weakly.

0152Figure 8 shows mmunofluorescent staining of DPV15b-PO and DPV15-PO conjugates after internalization in HeLa cells for 4 hours at 37°C. DPV-PO conjugates were incubated for 4 hours at an initial concentration of 75 µg/ml on HeLa cells, on 8 wells labtek glass slides. Revelation of peroxidase was performed using a primary monoclonal antibody against peroxidase, and a secondary anti mouse TRITC-conjugated antibody.

0153Figure 8 shows Immunofluorescent staining of DPV-PO conjugates after internalization in HeLa cells. Revelation of peroxidase was performed using a primary monoclonal antibody against peroxidase, and a secondary anti mouse TRITC-conjugated antibody.

2.3)

Influence of the initial concentration on the level of intracellular accumulation

.

0154All the preliminary experiments concerning the internalization of DPV-PO conjugates had been realized at an initial conjugate concentration of 75 µg/ml. In order to verify if the internalisation mechanism could be saturated, the influence of the initial conjugate concentration on the level of intracellular accumulation of the conjugates was studied.

0155The internalization figure of DPV15b-PO and DPV15-PO shows that no plateau is reached within the range of concentrations that were tested.

0156Figure 9 shows internalization of DPV-PO conjugates as a function of the initial conjugate concentration. HeLa cells cultivated on glass labtek slides for 24 hours were incubated for 4 hours in the presence of DPV-PO conjugates at the initial concentrations indicated on the figure. Internalized PO was quantified after extensive treatment with trypsin to eliminate surface bound material, and subsequent cell lysis. Results are given in picogram PO per 1000 cells.

0157All subsequent experiments were realized with an initial DPV-PO concentration of 25 µg/ml.

2.4)

Influence of the temperature on the internalization of DPV-PO conjugates

.

0158In order to determine if the internalization of DPV-PO conjugates was an energy-dependent phenomenon, we performed quantitative experiments at either 37 or 4°C.

0159Figure 10 shows influence of the temperature on the level of internalization of DPV-PO conjugates. HeLa cells cultivated on glass labtek slides for 24 hours were incubated for 4 hours in the presence of DPV-PO conjugates at an initial concentration of 25µg/ml, at either 37 or 4°C. Internalized PO was quantified after extensive treatment with trypsin to eliminate surface bound material, and subsequent cell lysis. Results are given in picogram PO per 1000 cells.

0160As seen in figure 10, internalization of DPV-PO conjugates is inhibited at 4°C, suggesting an active endocytosis phenomenon.

2.5)

Influence of the cell surface glycosaminoglycans (GAGs) on the internalization of DPV-PO conjugates

.

0161DPVs originate from human heparin-binding proteins and consequently bind to heparin <i>in vitro.</i> In order to verify that a step of GAGs-binding was necessary <i>in vivo,</i> we performed internalization experiments in both CHO-K1 and PgsA-745 cells, which is a clone of CHO devoid of xylosyltransferase and thus does not produce detectable levels of proteoglycans (Esko et al., 1985; Rostand and Esko, 1997).

0162Figure 11 represents comparative levels of internalization of DPV15b-PO and Cys-PO in CHO and PgsA-745 cells. CHO or PgsA-745 cells cultivated on glass labtek slides for 24 hours were incubated for 4 hours at 37 °C in the presence of DPV-PO conjugates at an initial concentration of 25µg/ml. Internalized PO was quantified after extensive treatment with trypsin to eliminate surface bound material, and subsequent cell lysis. Results are given in picogram PO per 1000 cells.

0163Comparison of the level of conjugates internalization in CHO-K1 cells and PgsA-745 cells (figure 11) shows that the absence of proteoglycans at the surface of PgsA-745 cells leads to an important decrease of the level of internalized conjugates, thus confirming the binding to GAGs as a first step in DPV-PO internalization.

2.6)

Heparin inhibition of the internalization of DPV-PO conjugates

.

0164In order to confirm the binding of DPVs to GAGs as a prerequisite for the internalization of the conjugates, we realized internalization experiments in the presence of heparin in the incubation medium. Heparin should bind to the DPV, and prevent its binding to the cell surface and subsequent internalization.

0165Figure 12 shows inhibitory effect of heparin on the intracellular accumulation of DPV-PO conjugates. HeLa cells cultivated on glass labtek slides for 24 hours were preincubated with the indicated concentrations of heparin for 1 hour at 37°C. Cells were then incubated for 4 hours in the presence of DPV-PO conjugates at 25µg/ml in cell culture medium containing the same quantity of heparin. Internalized PO was quantified after extensive treatment with trypsin to eliminate surface bound material, and subsequent cell lysis. Results are given in picogram PO per 1000 cells.

0166As seen in figure 12, incubation of the conjugates in the presence of heparin inhibits its internalization in HeLa cells, thus confirming the interaction between GAGs and DPVs.

2.7)

Poly-L-Lys inhibition of the internalization of DPV-PO conjugates

.

0167The inhibition of DPV-PO internalization in cells presenting defects in glycosaminoglycan synthesis (PgsA-745 cells compared to CHO cells), as well as the inhibition of internalization of DPV-conjugates in the presence of Heparin in the cell culture medium show that cell-associated heparan-sulfate proteoglycans function as cell surface binding sites for extracellular DPV internalization.

0168In order to verify this hypothesis, we tested the inhibition of DPV-PO internalization in HeLa cells in the presence of Poly-L-Lysine in the incubation medium : positively charged poly-L-Lys should bind to the negative charges of the cell surface, and prevent the binding of DPVs.

0169Figure 13 shows nhibitory effect of Poly-L-Lys on the intracellular accumulation of DPV-PO conjugates. HeLa cells cultivated on glass labtek slides for 24 hours were preincubated with the indicated concentrations of poly-L-Lys for 1 hour at 37°C. Cells were then incubated for 4 hours in the presence of DPV-PO conjugates at 25µg/ml in cell culture medium containing the same quantity of poly-L-Lys. Internalized PO was quantified after extensive treatment with trypsin to eliminate surface bound material, and subsequent cell lysis. Results are given in picogram PO per 1000 cells.

0170As seen in figure 13, there is a strong inhibition of DPV-PO internalization. The IC₅₀ (concentration at which 50 % of the maximum internalization is achieved) is situated around 25 µg/ml poly-L-Lys in HeLa cells.

0171These experiments show that a masking of the negative charges that are present around the cells is sufficient to inhibit DPV internalization, when it is conjugated to peroxidase.

<u>Example 2 : Internealization of control molecule without biological effect (Antibody anti-Peroxidase)</u>.

1) <u>Materials and Methods.</u>

1.1)

Nature of the ligand

.

0172Anti-Peroxidase Immunoglobulin (AntiPO-IgG) was chosen to represent the capacity of DPV15 and DPV15b to internalize very high molecular weight proteins (150 000 Da). <ul id="ul0006" list-style="dash" compact="compact"><li>Monoclonal anti-PO antibodies purified from ascite liquid by chromatography on protein G-Sepharose columns: 2 mg/mL in buffer phosphate 0.1M pH 7.4. (Origin : Diatos - TT).</li><li>Crosslinker : Succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC, Pierce)</li><li>Peptide Vectors : DPV15, DPV15b.</li><li>Vivaspin (Vivascience) : ultrafiltration membrane (cutoff threshold = 10000 or 30000 daltons) for concentration and purification of IgG and the elimination of excess reagents.</li><li>Solutions and buffers : <ul id="ul0007" list-style="none" compact="compact"><li>. Phosphate 0.1 M pH 7.4 (potassium phosphate)</li><li>. Dimethyl formamide (DMF)</li><li>. Conjugation buffer :<img file="EP1512696A1_D0006.tif" /></li><li>. NaCl 0.15 M</li><li>. NaCl 0.5 M</li></ul></li></ul>

1.2)

Conjugation protocol

.

0173The conjugation method involves four-steps : <ul id="ul0008" list-style="none" compact="compact"><li>Activation of IgG with the crosslinker (SMCC, Pierce)</li><li>Filtration of activated IgG on Vivaspin</li><li>Conjugation with DIATOS peptide</li><li>Elimination of free peptide</li></ul>

a)

SMCC activation of the immunoglobulin

.

0174<ul id="ul0009" list-style="dash" compact="compact"><li>Dissolve 2mg IgG in 1mL of phosphate buffer 0.1M pH 7.4</li><li>Dissolve 200 µg of SMCC in 20 µL of Dimethylformamide (DMF)</li><li>Add 11.1 µL of SMCC to the IgG solution (ratio : 25 SMCC / IgG)</li><li>Mix and incubate for 30-40 min at room temperature</li></ul>

b)

Filtration of the activated IgG

.

0175<ul id="ul0010" list-style="dash" compact="compact"><li>Add 1-2 mL of conjugation buffer into the activated IgG preparation and centrifuge in Vivaspin 10-15 min, 3300 g, 20°C.</li><li>Add 2 mL of conjugation buffer.</li><li>Centrifuge again and repeat this step twice.</li></ul>

c)

Conjugation with peptide

.

0176<ul id="ul0011" list-style="dash" compact="compact"><li>Dissolve 600 µg of DIATOS peptide in 60 µL of the conjugation buffer.</li><li>Add 54.5 µL of DIATOS peptide to IgG-SMCC (Ratio : 12 pept / IgG-SMCC).</li><li>Mix and incubate 3 hours at room temperature.</li></ul>

d)

Elimination of uncoupled peptide and excess reagents

.

0177<ul id="ul0012" list-style="dash" compact="compact"><li>Add 1 mL of 0.5M NaCl into the conjugated IgG preparation.</li><li>Concentrate IgG-SMCC-peptide in Vivaspin. Centrifugation 10-15 min, 3300g, 20°C.</li><li>Add 2 mL of 0.15 M NaCl and concentrate the conjugate again.</li><li>Repeat this last step one time.</li></ul>

0178A control was made which consists of AntiPO IgG linked to Cystein.

1.3)

Conservation of the conjugates

.

0179DPV-AntiPO IgG are kept in 100 µl frozen aliquots, diluted in 0.15 M NaCl.

1.4)

Characterization of the conjugated compounds

.

a)

SDS-PAGE.

018012 µg of each sample are loaded on a 10 % acrylamide SDS-PAGE gel.

0181Migration 100 V - 1h.

0182Staining of the gel with brilliant blue coomassie solution for 1 hour.

0183Destraining for 1 hour in H₂O / Ethanol / Acetic acid (6V / 3V / 1V).

0184Figure 14 shows example of SDS-PAGE separation of the DPV-Anti PO IgG conjugates. Approximately 12 µg of each conjugate was loaded on a 10 % SDS-PAGE gel before migration at 100 V, and subsequent coomassie blue staining. <ul id="ul0013" list-style="none" compact="compact"><li>Lane 1 : Molecular Weight standard</li><li>Lane 2 : AntiPO IgG</li><li>Lane 3 : DPV 15-AntiPO IgG conjugate.</li><li>Lane 4 : DPV 15b-AntiPO IgG conjugate.</li></ul>

0185Figure 14 shows an increase of molecular weight after coupling, for both heavy and light chains of the IgG. The 25 kDa band in lane 2 (light chain of the IgG) is lower than the bands in lanes 3 and 4. The presence of several bands between 25 and 30 kDa in lanes 3 and 4 is an indication of a heterogeneous coupling. The band corresponding to the heavy chain of the IgG (50 kDa band in lane 2) is also higher in lanes 3 and 4, indicating a coupling of the DPV on both chains of the IgG.

0186The important heterogeneity of conjugation does not allow the exact determination of the number of conjugated DPVs per IgG molecule by SDS-PAGE analysis.

b)

ELISA test on Heparin coated plates

.

0187DPV-AntiPO conjugates and controls (free AntiPO IgG and Cys-AntiPO IgG) are loaded on an ELISA plate previously coated with 5 µg/ml heparin (so that only conjugated compounds will bind and react with PO).

0188Samples are diluted to a final 10 µg/ml concentration in PBS-Tween. Subsequent _ dilutions are then performed.

0189Conjugates are incubated on the plate for 1 h at 37 °C, and washed 3 times in PBS-Tween.

0190PO is incubated at 1 µg/ml for 1 hour at 37 °C in every well, then washed 5 times in PBS containing 0.1% Tween.

0191PO substrate is then added (1 pill of 5 mg OPD (Sigma) + 10 ml citrate / citric acid buffer 0.1M, pH5.5 + 100µl H₂O₂ 3%)

0192Reaction is stopped with 50µl H₂SO₄ 2N after 5 min.

0193OD is read at 490 nm.

0194This test allows the verification of the presence of DPVs on the IgG molecules. Nevertheless, the affinity of each DPV for heparin being different, it does not allow quantification of the compounds in solution. This quantification is made by measuring OD₂₈₀, knowing that 1.4 OD unit = 1 mg/ml conjugate.

1.5)

Internalization protocols

.

0195Internalization experiments were realized in both HCT116 (colorectal carcinoma) and HeLa (cervical adenocarcinoma) cell lines. Intracellular accumulation was evaluated at a single time point (4 hours).

a)

Quantitative assay.

0196Cells were routinely seeded at Day 0 : 3.6.10⁴ cells/cm² for HeLa cells, or 7.10⁴ cells/cm² for HCT116 cells, in 2 wells labtek glass slides (4 cm²/well). Penetration studies were performed at Day 1.

0197<u>Protocol</u> : (Proceedings MM-07/11/01v1)

0198Dilute conjugates in DMEM + 10 % SVF at 100 µg/ml.

0199Take culture medium off the cells

0200Incubate conjugates for 4 hours, 37 °C, 5% CO₂ - 400 µl/well (i.e. 5 µg/well) - 2 wells per conjugate.

0201Rinse cells 3 times in PBS.

0202Incubate the cells in 200 µl Trypsin-EDTA for 30 min at 37°C.

0203Resuspend cells in 400 µl of complete culture medium.

0204Count cells.

0205Centrifuge and rinse cells twice in ice cold PBS.

0206Resuspend in 220 µl cold lysate buffer (0.1M Tris pH8, 0.5 % NP40).

0207Incubate 15 min at 4°C.

0208Centrifuge cell lysates.

0209Distribute cell lysates in a 96 wells plate that was previously coated with anti mouse IgG (twice 100 µl). Prepare a standard curve for antiPO IgG from 10ng/ml.

0210Dilute cell lysates _ in PBS-Tween and prepare a standard curve for anti PO IgG at 10 ng/ml.

0211Incubate 1 h at 37°C, and overnight at 4°C.

0212Rinse 3 times in PBS-Tween.

0213Incubate Peroxidase 1 µg/ml in PBS-Tween, for 1h at 37°C.

0214Rinse 3 times in PBS-Tween.

0215Add peroxidase substrate (1 pill OPD + 10 ml citrate-citric acid buffer 0.1 M, pH5.5 + 100 µl 3 % H₂O₂)

0216Stop the reaction after 9 min by adding 50 µl H₂SO₄ 2 N.

0217Read absorbance at 490 nm and compare to the values of the standard curve.

b)

Qualitative evaluation of the internalization of DPV-antiPO IgG conjugates

.

-

PO-Peroxidase substrate staining

.

0218Cells were routinely seeded at Day 0 : 3.6.10⁴ cells/cm² for HeLa cells, or 7.10⁴ cells/cm² for HCT116 cells, in 8 wells labtek glass slides (0.7 cm²/well). Penetration studies were performed at Day 1.

Protocol

(Proceedings FC05/11/01v1) :

0219Dilute conjugates in complete culture medium at 100 µg/ml.

0220Take culture medium off the cells

0221Incubate conjugates for 4 hours, 37 °C, 5% CO₂ - 100 µl/well (i.e.10µg/well).

0222Rinse cells 3 times in PBS.

0223Fix in cold Ethanol for 5 min at -20 °C.

0224Rinse in PBS at RT.

0225Add PO (10 µg/ml in complete culture medium) 1 h at room temperature.

0226Rinse 3 times in PBS.

0227Add peroxidase substrate (di-aminobenzidine, 1 tablet in 10 ml H₂O + 330 µl H₂O₂ 3%)

0228Rinse 3X in PBS.

0229Take pictures

-

TRITC-conjugated anti mouse IgG staining

.

0230Cells were routinely seeded at Day 0 : 3.6.10⁴ cells/cm2 for HeLa cells, or 7.10⁴ cells/cm_ for HCT116 cells, in 8 wells labtek glass slides (0.7 cm_/well). Penetration studies were performed at Day 1.

0231<u>Protocol</u> (Proceedings FC04/11/01v1):

0232Dilute conjugates in complete culture medium at 100 µg/ml.

0233Take culture medium off the cells

0234Incubate conjugates for 4 hours, 37 °C, 5% CO₂ - 100 µl/well (i.e.10µg/well).

0235Rinse cells 3 times in PBS.

0236Fix in cold Methanol/Acetone (1/1) for 5 min at -20° C.

0237Rinse in PBS at RT.

0238Block in PBS + 5 % Donkey serum (sol A) for 30 min at RT.

0239Incubate with TRITC-conjugated anti mouse 7µg/ml in sol. A - 30 min in the dark at RT.

0240Rinse in sol A, then in PBS.

0241Equilibrate in equilibration buffer, and mount in <i>Slow Fade Light Antifade Kit</i> with DAPI (Molecular probes S-24636).

2) <u>Results.</u>

2.1)

Quantitative penetration

.

0242Figure 15 shows quantitative penetration of the DPV-AntiPO IgG conjugates in HCT116 cells. Cell lysis was performed after 4 hours of incubation at an initial DPV-AntiPO IgG conjugates concentration of 100 µg/ml. Results are given as the mean value obtained in three independent experiments, all realized in duplicates.

0243Table 4 represents net quantities of DPV-antiPO IgG conjugates internalized in HCT 116 cells. Results are given in picograms / 1000 cells, as the mean of three independent experiments. <tables id="tabl0004" num="0004"><table frame="all"><title>Table 4</title><tgroup cols="3" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="52.50mm" /><colspec colnum="2" colname="col2" colwidth="52.50mm" /><colspec colnum="3" colname="col3" colwidth="52.50mm" /><thead valign="top"><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="center">pg/1000 cells</entry><entry namest="col3" nameend="col3" align="center">standard deviation</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">DPV15-aPO</entry><entry namest="col2" nameend="col2" align="char" char=",">15,2</entry><entry namest="col3" nameend="col3" align="char" char=",">8,9</entry></row><row><entry namest="col1" nameend="col1" align="left">DPV15b-aPO</entry><entry namest="col2" nameend="col2" align="char" char=",">21,4</entry><entry namest="col3" nameend="col3" align="char" char=",">6,4</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Cys-aPO</entry><entry namest="col2" nameend="col2" align="char" char=",">1,1</entry><entry namest="col3" nameend="col3" align="char" char=",">0,9</entry></row></tbody></tgroup></table></tables>

0244Figure 16 shows quantitative penetration of the DPV-antiPO IgG conjugates in HeLa cells. Cells were incubated for 4 hours in the presence of the conjugates at an initial concentration of 100µg/ml. Results are given as the mean value obtained in three independent experiments, all realized in duplicates.

0245Table 5 represents net quantities of DPV-antiPO conjugates internalized in HeLa cells. Results are given as the mean value of three independent experiments, in picograms / 1000 cells. <tables id="tabl0005" num="0005"><table frame="all"><title>Table 5</title><tgroup cols="3" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="52.50mm" /><colspec colnum="2" colname="col2" colwidth="52.50mm" /><colspec colnum="3" colname="col3" colwidth="52.50mm" /><thead valign="top"><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="center">pg/1000 cells</entry><entry namest="col3" nameend="col3" align="center">standard deviation</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">DPV15-aPO</entry><entry namest="col2" nameend="col2" align="char" char=",">21,5</entry><entry namest="col3" nameend="col3" align="char" char=",">3,4</entry></row><row><entry namest="col1" nameend="col1" align="left">DPV15b-aPO</entry><entry namest="col2" nameend="col2" align="char" char=",">55,5</entry><entry namest="col3" nameend="col3" align="char" char=",">17,6</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Cys-aPO</entry><entry namest="col2" nameend="col2" align="char" char=",">1,7</entry><entry namest="col3" nameend="col3" align="char" char=",">2,2</entry></row></tbody></tgroup></table></tables>

0246Figure 17 represent a comparison of the level of internalization of the DPV-antiPO conjugates in HeLa and HCT116 cells. The level of internalization depends both on the cell line, and on the DPV.

0247Table 6 represents number of conjugate molecules internalized in each cell type (million conjugate molecules per cell). <tables id="tabl0006" num="0006"><img file="EP1512696A1_D0007.tif" /></tables>

2.2)

Qualitative evaluation of the internalization of DPVs-antiPO IgG

.

0248DPV-AntiPO conjugates were incubated with HeLa cells grown on glass labtek slides (4 hours incubation of a 100 µg/ml solution in cell culture medium, at 37 °C). The experiment was realized with the same peptide-AntiPO IgG conjugates as the ones used in the quantitative experiments described above.

0249As shown in figures 5 to 8, in HeLa cells, intracellular localization of PV15b- and DPV15-antiPO IgG conjugates is mainly localized in the nucleus of the cells (weak staining of the cytoplasm, corresponding partly to the quantity of conjugates still in transit between the membrane and the nucleus of the cells, and partly to the proportion of conjugate which final localization would be cytoplasmic).

0250Figure 18 shows localization of DPV15-antiPO IgG and DPV15b-antiPO IgG conjugates in HeLa cells. DPV-antiPO IgG conjugates were incubated for 4 hours at an initial concentration of 100 µg/ml on HeLa cells, on 8 wells labtek glass slides. Revelation of the conjugate was performed using peroxidase visualized by its substrate : di-aminobenzidine. Pictures were taken with a Nikon coolpix numeric camera, maximum zoom, after visualization on a Leica microscope (20 X lens + 0.63 X adaptator). The fact that the DPV-antiPO IgG still recognize its antigen (namely Peroxidase) shows that this IgG is still active once coupled to the DPV and internalized inside the cell.

0251Figure 19 shows details of HeLa cells after DPV15b-antiPO IgG internalization. The internalization of the conjugates and the acquisition of the image were realized in the same conditions as for figure 18. Enlargement was performed in a second step.

0252Figure 20 shows immunofluorescent staining of DPV15-antiPO IgG and DPV15b-antiPO IgG conjugates after internalization in HeLa cells for 4 hours at 37°C. DPV-antiPO IgG conjugates were incubated for 4 hours at an initial concentration of 100 µg/ml on HeLa cells, on 8 wells labtek glass slides. Revelation of the IgG was performed using an anti mouse TRITC-conjugated antibody.

0253Figure 21 shows details of HeLa cells after DPV15b-antiPO IgG conjugates internalization. The internalization of the conjugates and the acquisition of the images were realized in the same conditions as for figure 8. Enlargement was performed in a second step.

0254Figure 22 shows immunofluorescent staining of DPV15b-antiPO IgG conjugates after internalization in HCT116 cells for 4 hours at 37°C. DPV-antiPO IgG conjugates were incubated for 4 hours at an initial concentration of 100 µg/ml on HCT116 cells, on 8 wells labtek glass slides. Revelation of the IgG was performed using an anti mouse TRITC-conjugated antibody.

0255Figure 23 shows the intracellular localization of DPV15b-IgG conjugates in HCT116 cells. The final intracellular localization of the two conjugates was similar in HeLa and HCT116 cells.

<u>Example 3 : Internealization of control molecule without biological effect (Tetra-Methyl-Rhodamine "TMR").</u>

1) <u>Materials and Methods.</u>

1.1)

Nature of the ligand.

0256Tetra-Methyl-Rhodamine was chosen to represent the capacity of the DPV15 and DPV15b to internalise a small molecule.

0257Tetramethylrhodamine-5-maleimide. (Molecular Probes T-6027)

1.2)

Conjugation protocol

.

0258Dissolve 5 mg of TMR-5-maleimide in 207.7 µl of Dimethylformamid (DMF) (final concentration 50 mM)

0259Dissolve x mg of DPV in y µl of DMF (final concentration 10mM)

0260Mix 200 µl of TMR solution and 700 µl of DPV solution and incubate 2 hours at room temperature in dark

0261Ad 2ml H₂O and 8 ml Dichlorométhane (DCM).

0262Mix and centrifuge 2 minutes at 3000g.

0263Take aqueous phase (upper phase)

0264Repeat step 4 to 6 twice.

1.3)

Conservation of the conjugate

.

0265DPV-TMR conjugates are kept as dry powder at -80°C or 4°C under argon.

1.4)

Internalization protocol

.

a)

Quantitative assay

.

0266Cells were routinely seeded at Day 0: 1.10⁵ cells/cm² for HeLa cells, or 2.10⁵ cells/cm² for HCT116 cells, in 2 well labtek glass slides (4 cm²/well). Penetration studies were performed at Day 1.

Protocol

:

0267Dilute conjugates in complete culture medium (+10%SVF) at 20µM

0268Take culture medium off the cells

0269Incubate conjugates for 2 hours, 37°C, 5% CO₂ - 600µl/well

0270Rinse 2 times in complete culture medium and 2 times in PBS

0271Incubate the cells in 400µl Trypsin-EDTA for 30 min at 37°C

0272Resuspend cells in 600µl of complete culture medium (+10% SVF)

0273Count cells

0274Centrifuge and rinse cells twice in PBS

0275Resuspend in 1ml cold lysate RIPA buffer

0276Incubate 30 min at 4°C

0277Prepare a standard curve for cystein-TMR at 200nM

0278Fluorescence is counted on a BioRad fluorimeter, (excitation 480 nm and emission 590 nm).

b)

Qualitative evaluation of the internalisation of DPV-TMR conjugates

.

0279Cells were routinely seeded at Day 0: 1.10⁵ cells/cm² for HeLa cells, or 2.10⁵ cells/cm² for HCT116 cells, in 8 well labtek glass slides (0.7 cm²/well). Penetration studies were performed at Day 1.

Protocol

:

0280Dilute conjugates in complete culture medium (+10%SVF) at 20µM

0281Take culture medium off the cells

0282Incubate conjugates for 4 hours, 37°C, 5% CO₂ - 100µl/well

0283Rinse 2 times in complete culture medium and 2 times in PBS

0284Fix in 4%PFA 20min at room temperature

0285Rinse 3 times in PBS

2) <u>Results.</u>

02862.1) <u>Quantitative intracellular accumulation</u>.

0287Figure 24 shows quantitative penetration of the DPV15-and DPV15b-TMR in HeLa cells. Cell lysis was performed after 2 hours of incubation at an initial DPV-TMR conjugates concentration of 20µM. Results are given as the mean value obtained in two independent experiments.

0288Table 7 represents net quantities of DPV-TMR conjugates internalized in HeLa cells. Results are given in picograms/1000 cells. <tables id="tabl0007" num="0007"><img file="EP1512696A1_D0008.tif" /></tables>

0289Figure 25 shows quantitative penetration of the DPV15-and DPV15b-TMR in HCT116 cells. Cell lysis was performed after 2 hours of incubation at an initial DPV-TMR conjugates concentration of 20µM. Results are given as the mean value obtained in two independent experiments.

0290Table 8 represents net quantities of DPV-TMR conjugates internalized in HCT116 cells. Results are given in picograms/1000 cells. <tables id="tabl0008" num="0008"><img file="EP1512696A1_D0009.tif" /></tables>

0291Figure 26 represents a comparison of the level of internalization of the DPV-TMR in HeLa and HCT116 cells.

0292Table 9 shows an estimated number of conjugated molecules internalized in each type cell type (million conjugate molecules per cells) and ratio of intracellular accumulation of DPV-TMR conjugates in HeLa versus HT116 cells. <tables id="tabl0009" num="0009"><img file="EP1512696A1_D0010.tif" /></tables>

2.2)

Qualitative evaluation of the internalisation of DPV-TMR in HeLa cells

.

0293Figure 27 shows cytoplasmic punctuate staining of DPV15b-TMR after internalisation in HeLa cells. Conjugates were incubated with HeLa cells 2 hours at 37°C at an initial concentration of 20µg/ml.

0294Figure 28 shows cytoplasmic punctuate staining of DPV15b-TMR after internalisation in HCT116 cells. Conjugates were incubated with HCT116 cells 2 hours at 37°C at an initial concentration of 20µg/ml. Cell nuclei are stained with DAPI.

2.3)

Influence of the temperature on the internalization of DPV15b-TMR conjugates

.

0295Figure 29 shows the influence of the temperature on the level of internalisation of DPV15b-TMRconjugates. HeLa cells were incubated 2 hours in the presence of DPV15b-TMR conjugates at an initial concentration of 25 µg/ml, at either 37 or 4°C. Cell were then trypsinized before being lysed in RIPA buffer, and fluorescence was quantified. Each value is the result of three independent experiments, each in duplicate.

2.4)

Influence of the cell glycosaminoglycans on the internalisation of DPV-TMR conjugates

.

0296Figure 30 shows quantification of DPV15b-TMR conjugates internalisation in CHO and PgsA-745 cells. Incubation took place for 2 hours at 37°C, before trypsinization and lysis in RIPA buffer for 30 minutes at 4°C. Each value is the result of three independent experiments.

<u>Example 4 : Activity of conjugated active molecule (Chlorambucil).</u>

1) <u>Nature of the ligand</u>.

0297Chlorambucil is an inhibitor of DNA and RNA synthesis. It is an alkylating agent causing intra- or inter-cross-links in DNA molecules. Reactive groups are the two Cl-groups. Its formula is given in figure 31

0298Resistance to chlorambucil has been linked to an increase in (i) the efflux pump MRP1, and (ii) the glutathione S-transferases (GSTs) that are involved in the detoxification of electrophilic toxins (Morrow CS., 1998, J. <i>Biol</i>. <i>Chem.,</i> 273:20114).

0299In clinic, the major problem is the risk of induction of secondary leukemias following therapy with chlorambucil (Travis LB., 1994, <i>J. Natl</i>. <i>Cancer Inst</i>., 86:1450).

0300Coupling Peptide Vectors (DPVs) to chlorambucil has 2 advantages: <ul id="ul0014" list-style="dash" compact="compact"><li>DPVs overcome multidrug resistant (MDR) phenotype due to expression of membrane efflux pumps such as the P-glycoprotein (P-gp) or the multidrug resistance proteins (MRPs), that can extrude a wide range of anticancer drugs.</li><li>DPVs increase solubility of chlorambucil in H₂O.</li></ul>

0301Therefore, DPV-chlorambucil conjugates may be more soluble and more active in resistant tumors.

2) <u>Conjugation.</u>

2.1)

Materials.

0302DPV15-E-Chl conjugate was compared to non-conjugated Chl (Fluka, Cat# 23125).

0303Chl is not soluble in aqueous solutions but it may be solubilized in ethanol.

0304For viability assays, Chl was solubilized in ethanol at 50 mM then diluted in culture medium at 1 mM (so the highest concentration tested on cells contained 2% ethanol).

0305Molar extinction coefficient at 258 nm was calculated for Chl: 17.900 ± 1.200

0306Exact concentration of Chl and DPV15-E-Chl solutions was calculated after dilution 1/100 in H₂O, measurement of OD_258nm and using the following formula:<maths id="math0001" num=""><math display="block"><mrow><msub><mrow><mtext>[molar concentration] = OD</mtext></mrow><mrow><mtext>258nm</mtext></mrow></msub><mtext>/17.900</mtext></mrow></math><img file="EP1512696A1_D0011.tif" /></maths>

2.2)

Conjugation protocol

.

0307Chlorambucil has been conjugated to DPV15 with an ester link _(E) on the OH group as shown on figures 32 and 33.

0308The two reactive groups (Cl-) are free, therefore the conjugate does not need to be cleaved to be active.

0309DPV15:         _{NH<sub2>2</sub2>}-L R R E R Q S R L R R E R Q S R-Cys-_COOH (16 + 1 aa)

0310nuclear localization (DPV15-PO &amp; DPV15-mAb anti-PO)

0311DPV15-_E-Chlorambucil:

03121 batch:11/10/2001 70 mg (soluble in water at ≥ 10 mg/ml), molecular weight = 2825.15

0313HPLC purity - 90%, net peptide content = 60% (counterion = TFA)

0314HPLC analysis showed that preparation contains 90% of DPV15-_E-Chl and 10% of "modified" DPV15-_E-Chl with a different absorbance spectrum. This modification is not due to proteolysis of the ester link and is most likely due to instability of Chl as previously described (Bosanquet AG., 1986, <i>Cancer Chemother</i>. <i>Pharmacol</i>., 18:176). It could be due to (i) modification of the aromatic nucleus of Chl or (ii) interaction of the 2 Cl- atoms contained in Chl with H₂O molecules. We would have to perform mass spectrometry analysis, in order to identify this component.

0315After overnight incubation at room temperature and protected from light, both Chl (0,1 mg/ml in H₂O + 0.1% TFA) and DPV15-_E-Chl (0.5 mg/ml in H₂O + 0.1% TFA) are degraded (50% degradation) (see Fabien Ribes' lab book).

3)

Viability assay.

3.1)

Human cell lines.

0316<i>HCT116</i> :human colon carcinoma (origin : ATCC #CCL-247)

0317<i>HT29</i> : human colon carcinoma, low P-gp expression (origin : ATCC #HTB-38)

K562

: human chronic myelogenous leukemia (CML) (origin : ATCC #CCL-243).

3.2)

Viability Assay.

0318Viability assays were performed as described in <i>procedure # KG-10</i>/<i>12</i>/<i>01-v1</i>.

0319Briefly, cells are seeded in 96-well plates and incubated with increasing concentrations of drugs (i) for 1 hour then cells are rinsed and incubated with fresh medium without drugs for 48 hours, or (ii) for 48 hours. A WST-1 test (from Roche) was performed and IC₅₀ values (drug concentration that inhibits 50% of cell viability) were estimated from sigmoidal regressions.

4)

<u>In Vitro</u>

efficacy

.

0320DPV15-_E-Chl conjugate was compared to non-conjugated Chl and 5FUra for the inhibition of in vitro cell proliferation of human carcinoma and leukemia cells. We calculated IC₅₀ values = drug concentration that inhibits 50% of cell viability. <tables id="tabl0010" num="0010"><img file="EP1512696A1_D0012.tif" /></tables>

5)

conclusions - discussion

.

5.1)

In term of solubilization

.

0321Conjugation of DPV15 to Chlorambucil led to a water soluble conjugate.

5.2)

In term of efficacy on tumor cell growth

.

0322<ul id="ul0015" list-style="dash" compact="compact"><li>in K562 leukemia, DPV15-_E-Chl conjugate is much more efficient than Chl (≥16-fold after short exposure, and 8-fold after long exposure).</li><li>in HCT116 colon carcinoma, DPV15-_E-Chl conjugate is more efficient than Chl (12-fold after short exposure, and 8-fold after long exposure) and as efficient as the drug that is used in clinic for this indication, namely 5FUra.</li><li>in HT29 colon carcinoma, resistant to 5FUra, DPV15-E-Chl conjugate is more efficient than Chl after short exposure (11-fold) and is more efficient than 5FUra after short exposure (≥17-fold).</li></ul>    (^#: there is no explanation for the unexpected high value obtained after long exposure).

0323The lack of activity for Chl is not due to the solvent used for solubilization (ethanol) as we obtained the same results for DPV15-E-Chl solubilized in water and in ethanol (data not shown).

0324Nevertheless, the fact that we did not detect any activity for Chl may be due to the fact that we did not obtain a good solubilization of Chl in ethanol. In literature, an efficacy of Chl has been described in vitro on B-CLL with a median IC₅₀ of 40.5 mM (Silber R., 1994, <i>Blood,</i> 84:3440).

<u>Example 4 : Activity of conjugated active molecule (Paclitaxel)</u>.

1) <u>Nature of the ligand</u>.

0325Taxanes are cytotoxic agents that inhibit the mitotic spindle during cell division through inhibition of β-tubulin depolymerisation (Nogales E., 1999, <i>Cell. Mol. Life Sci.</i> 56:133). The two taxanes in clinical use are paclitaxel (Taxol®) and docetaxel (Taxotere®). Paclitaxel was extracted in the late 1960s from the bark of the Pacific Yew, <i>Taxus brevifolia</i> (Wall ME., 1995, <i>Cancer Res.</i> 55:753). Docetaxel was obtained in the mid 1980s as part of a major chemistry effort to develop a semi-synthesis process to obtain paclitaxel and analogs using 10-deacetyl baccatin III, a precursor extracted from the needles of the European Yew treen <i>Taxus baccata</i> (Gueritte-Voegelein F., 1991, <i>J. Med. Chem</i>., 34:992).

0326The mechanims of resistance described most often for paclitaxel is the multidrug-resistance (MDR) phenotype mediated by the 170 kDa P-glycoprotein( P-gp) membrane efflux pump encoded by the <i>mdr1</i> gene and that can extrude a wide range of anticancer drugs. Overexpression of this transport system is recognized as a relevant mechanism of resistance to Taxol® (Zunino F., 1999, <i>Drug Resist. Updat.</i> 2:351).

0327Paclitaxel is not soluble in water, and is solubilized in cremophor (polyoxyethylated castor oil) or ethanol. In clinic, administration of paclitaxel is intraveinous and these 2 excipients have been associated with hypersensitivity (HSR) in patients treated with paclitaxel.

0328Coupling Diatos Peptide Vectors (DPVs) to paclitaxel (PTX) could have 2 advantages: <ul id="ul0016" list-style="dash" compact="compact"><li>DPVs could overcome the MDR phenotype due to expression of P-gp.</li><li>DPVs may increase water solubility of paclitaxel.</li></ul>

0329Therefore, DPV-PTX conjugates may be more soluble and more active in resistant tumors.

2) <u>Conjugation</u>.

0330Paclitaxel (PTX) and DPV were conjugated.

0331DPV15/DPV3-_E-PTX conjugates were compared to : <ul id="ul0017" list-style="dash" compact="compact"><li>non-formulated paclitaxel from Hauser (Lot # Tech-6-00600-A)</li><li>clinical grade formulated Taxol® from Bristol-Myers Squibb (Lot # 01H25-A).</li></ul>

0332Paclitaxel is not soluble in aqueous solutions but it may be solubilized in polyoxyethylated castor oil (cremophor EL, Sigma cat#C5135).

0333For viability assays, paclitaxel was solubilized at 5 mM in water containing 20% cremophor EL, then diluted in culture medium at 500 µM (so the highest concentration tested on cells contained 2% of cremophor EL).

0334DPV15-E-PTX and DPV3-e-PTX conjugates was supplied by Laboratoire de Chimie Bioorganique et de Biologie Moléculaire et Cellulaire (LCBBMC). Ecole Nationale Supérieure de Chimie de Paris (ENSCP).

0335Paclitaxel (from Hauser) was conjugated to DPV15 and DPV3 with an ester link (E) on the 2'-OH group. This 2'-OH group is important for paclitaxel activity (see figure 34). Therefore, DPV-E-PTX conjugates are partially active, they are produgs that are fully active after cleavage of the ester link by esterases.

0336DPV15 :         _{NH<sub2>2</sub2>}-L R R E R Q S R L R R E R Q S R-Cys-_COOH (16 + 1 aa)

0337Nuclear localization : as reported in study on internalization of DPV-peroxidase conjugates and study on internalization of DPV-antibody anti peroxidase conjugates.

0338DPV3 :         _{NH<sub2>2</sub2>}-R K K R R R E S R K K R R R E S-Cys-_COOH (16 + 1 aa)

0339Cytoplasmic localization: as reported in study on internalization of DPV-peroxidase conjugates and study on internalization of DPV-antibody anti peroxidase conjugates.

0340DPV15-_E-PTX(see formula on figure 35.

0341Theoretical molecular weight: 3331.73

0342Solubility: soluble in water (≥ 10 mg/ml)

0343Counter-ion: TFA

03442 Lots: <ul id="ul0018" list-style="none" compact="compact"><li><u>DIAT0049</u> (ALL0050)55 mg (06/12/2001) HPLC purity >99%, net peptide content = 80%</li><li><u>DIAT0050</u> (ALL0050bis) 15 mg (06/12/2001) HPLC purity >99%, net peptide content = 88%</li></ul>

3)

Viability assay

.

3.1)

Human cell lines.

0345<i>OVCAR-3</i> : human ovary carcinoma (origin : ATCC #HTB-161)

0346<i>NCI-H1299</i> : human non small cell lung carcinoma (NSCLC) (origin: ATCC #CRL-5803)

0347<i>MES-SA</i>/<i>Dx5</i> : human uterine sarcoma, resistant to paclitaxel, expressing high P-gp (origin: ATCC #CCL-1977).

3.2)

Viability Assay.

0348Viability assays were performed as described in procedure "Test WST-1 de viabilité cellulaire sur cellules adhérentes" # KG-10/01/02-v1.

0349Briefly, cells are seeded in 96-well plates and incubated with increasing concentrations of drugs for 1 hour then cells are rinsed and incubated with fresh medium without drugs for 72 hours. A WST-1 test (from Roche) was performed and IC₅₀ values (drug concentration that inhibits 50% of cell viability) were estimated from sigmoidal regressions.

4)

Results.

0350DPV15-_E-PTX and DPV3-_E-PTX conjugates were compared to non-formulated paclitaxel (from Hauser), clinical grade formulated Taxol® (from BMS), Doxorubicin (Dox) and DPV1047-E-Dox conjugate.

0351We tested the inhibition of <i>in vitro</i> cell proliferation of human carcinoma cells, and we calculated IC₅₀ values = drug concentration that inhibits 50% of cell viability (mean value from n independent experiments ± standard deviation). <tables id="tabl0011" num="0011"><img file="EP1512696A1_D0013.tif" /></tables>

0352The cytotoxicity observed with free paclitaxel (from Hauser) solubilized in cremophor EL was not due to the solvent used for solubilization as we did not observe any cytotoxicity of the solvent alone, at the maximal concentration used (2%) (data not shown).

0353Comparison between non-formulated paclitaxel from Hauser (solubilized in Cremophor EL) and clinical grade formulated Taxol® from BMS showed the same efficacy (except in H1299 cells where Taxol® was 10-fold more efficient than paclitaxel).

In term of solubilization

.

0354Conjugation of DPV15 and DPV3 to paclitaxel with an ester link led to water soluble conjugates.

In terms of efficacy on in vitro tumor cell proliferation

.

0355<ul id="ul0019" list-style="dash" compact="compact"><li>in OVCAR-3 ovary carcinoma sensitive to doxorubicin and paclitaxel, both DPV-E-PTX conjugates are less efficient than paclitaxel (9-fold) and more efficient than doxorubicin and DPV1047-E-Dox conjugate (22-fold).</li><li>in H1299 non small cell lung carcinoma sensistive to doxorubicin and paclitaxel, both DPV-E-PTX conjugates are less efficient than paclitaxel (16-fold) and less efficient than doxorubicin and DPV1047-E-Dox conjugate (6-fold).</li><li>in MES-SA/Dx5 uterine sarcoma resistant to doxorubicin and paclitaxel, both DPV-E-PTX conjugates are more efficient than paclitaxel (15- to 31-fold), doxorubicin (10- to 22-fold) and DPV1047-E-Dox conjugate (3- to 5.5-fold).</li></ul><img file="EP1512696A1_D0014.tif" />